VYNE Therapeutics Inc. IPO Filing Research

S-4/A amended

S-4/A

Pre-IPO filing captured from the SEC submission timeline.

First tracked pre-IPO filing for this issuer.

2026-04-28 · 0001104659-26-050502

S-4 filed

S-4

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2026-03-31 · 0001104659-26-037932

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

Begins the tracked draft filing sequence after EFFECT.

VYNE Therapeutics Inc. filed a draft registration statement (DRS) for a proposed merger with Yarrow Bioscience, Inc., involving the exchange of Yarrow shares for VYNE stock and warrants. The merger includes a reverse stock split, new stock incentive plans, and shareholder approvals for governance changes. The filing outlines terms for converting Yarrow equity, adjusting VYNE options, and listing the combined company on Nasdaq under a new ticker.

2026-01-30 · 0001104659-26-008739

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2026-01-30 · 0001104659-26-008646

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2025-12-17 · 0001104659-25-121829

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

VYNE Therapeutics Inc. filed a Notice of Effectiveness for its S-3 registration statement on March 14, 2024, following a previous filing on November 22, 2023. The current filing confirms the effectiveness of the registration, but no substantive updates or changes to the company's operations, financials, or risk profile are disclosed in the provided text.

2024-03-14 · 9999999995-24-000666

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

VYNE Therapeutics Inc. filed an S-3 registration statement with the SEC, which became effective on November 22, 2023. This filing follows a prior S-3 registration from May 14, 2021, with the same CIK and company name. The current filing likely relates to a subsequent securities offering, though specific details about the offering's scope or purpose are not provided in the notice of effectiveness.

2023-11-22 · 9999999995-23-003422

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

39,266,980 shares · Gross proceeds $0.00

Common Stock · Exchange Nasdaq · Ticker VYNE · Pre-Funded Warrants exercisable for common stock · Selling stockholders only · Use of proceeds Proceeds from exercise of Pre-Funded Warrants

2023-11-22 · 0001104659-23-120742

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

Gross proceeds $14,385,585

Common Stock · Exchange Nasdaq Global Select Market · Ticker VYNE · Use of proceeds General corporate purposes · Underwriters Cantor Fitzgerald & Co.

2022-05-12 · 0001104659-22-059528

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows S-4/A and confirms the priced prospectus.

Gross proceeds $30,000,000

Common Stock · Exchange Nasdaq Global Select Market · Ticker VYNE · Use of proceeds Payment of registration expenses including legal and accounting fees · Underwriters Lincoln Park Capital Fund, LLC

2022-03-15 · 0001104659-22-033984

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 425 and confirms the priced prospectus.

Gross proceeds $50,000,000

Common · Exchange Nasdaq Global Select Market · Ticker VYNE · Underwriters Cantor Fitzgerald & Co.

2021-08-12 · 0001104659-21-104254

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

VYNE Therapeutics Inc. received SEC approval for its S-3 registration statement, confirming the effectiveness of its securities offering. The filing reiterates the company's plan to offer 21,097,046 shares of common stock to institutional investors at $2.37 per share, with proceeds intended for general corporate purposes. The offering, initially disclosed in a prior 424B5 filing, remains unchanged in structure and terms.

2021-05-14 · 9999999995-21-001961

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 425 and confirms the priced prospectus.

Price $2.37 · 21,097,046 shares · Gross proceeds $49,999,999

Common Stock · Exchange Nasdaq Global Select Market · Ticker VYNE · Use of proceeds for general corporate purposes

VYNE Therapeutics Inc. is offering 21,097,046 shares of common stock at $2.37 per share to institutional investors, with proceeds totaling $46.99 million. The offering is managed by H.C. Wainwright & Co., LLC as the exclusive placement agent. The company is an emerging growth company and highlights significant risks associated with its securities, including market volatility and operational uncertainties. The stock is listed on Nasdaq under the symbol 'VYNE.'

2021-01-27 · 0001104659-21-007790

424B2 filed

Prospectus supplement

Prospectus supplement that can carry timing details without itself confirming imminent trading.

Follows 425 in the pre-IPO sequence.

Price $1.85 · 27,050,000 shares · Gross proceeds $50,042,500

Common Stock · Exchange Nasdaq Global Select Market · Ticker MNLO · Over-allotment 4,057,500 · Underwriters Cowen Piper Sandler, LifeSci Capital

VYNE Therapeutics Inc. is offering 27,050,000 shares of common stock at $1.85 per share, with underwriters including Cowen Piper Sandler and LifeSci Capital. The filing provides detailed financial terms, including underwriting discounts, proceeds, and pro forma book value calculations. The company is an emerging growth company with significant risks outlined, including lack of profitability and tax implications for non-U.S. investors.

2020-06-05 · 0001104659-20-070350

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 425 and confirms the priced prospectus.

Common Stock · Exchange Nasdaq Global Select Market · Ticker MNLO · Underwriters Cowen Piper Sandler, LifeSci Capital

Menlo Therapeutics Inc. is offering shares of its common stock, listed on Nasdaq under 'MNLO.' The offering is underwritten by Cowen Piper Sandler and LifeSci Capital, with an expected delivery in book-entry form. The company, an emerging growth company, highlights significant risks in its prospectus, including uncertainties related to its merger with Foamix Pharmaceuticals Ltd. and market volatility.

2020-06-04 · 0001104659-20-069812

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows S-4 in the pre-IPO sequence.

On February 6, 2020, Menlo Therapeutics Inc. held a special meeting of stockholders to approve the merger with Foamix Pharmaceuticals Ltd., including the issuance of shares to Foamix shareholders and an adjournment of the meeting. The merger, structured as a stock swap, was approved by 83.72% of voting shares. The filing also references prior litigation related to the merger and amendments to the registration statement to address shareholder concerns.

2020-02-06 · 0001193125-20-026818

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

The current 8-K filing relates to Menlo Therapeutics Inc.'s merger with Foamix Pharmaceuticals Ltd., addressing shareholder litigation over disclosure adequacy. Menlo amended its registration statement to include detailed cost synergy projections ($50M+ annual savings starting 2021) and clarified strategic rationale for the merger. The filing also references ongoing legal challenges from shareholders alleging material omissions in the merger disclosure, which Menlo aims to resolve through voluntary amendments.

2020-01-28 · 0001193125-20-016912

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

The current filing outlines the merger between Menlo Therapeutics Inc. and Foamix Pharmaceuticals Ltd., with shareholder votes scheduled for February 6, 2020, and the closing expected by March 9, 2020. Post-closing, employee positions will be eliminated, and retention bonuses are offered to key personnel. The filing includes details about the merger process, regulatory approvals, and risks associated with the transaction.

2020-01-16 · 0001193125-20-008980

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

VYNE Therapeutics Inc. (through its affiliate Menlo Therapeutics) is advancing a merger with Foamix Pharmaceuticals Ltd., where Foamix will become a wholly-owned subsidiary. The transaction requires shareholder approval, scheduled for February 6, 2020, with closing expected by March 9, 2020. A retention bonus of $xx,xxx is offered to key employees to ensure continued employment post-closing. The filing includes details about the merger timeline, retention incentives, and references to the joint proxy statement/prospectus for shareholder information.

2020-01-16 · 0001193125-20-008979

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

VYNE Therapeutics Inc. (Menlo Therapeutics Inc.) filed a Form 8-K (425) disclosing shareholder litigation related to its proposed merger with Foamix Pharmaceuticals Ltd. The filing highlights a lawsuit alleging material omissions in the joint proxy statement/prospectus, with defendants denying merit. It also references the effective registration statement for the merger, emphasizing the need for shareholders to review materials before voting. The merger terms include contingent stock rights (CSRs) tied to clinical trial outcomes for Serlopitant, with ownership percentages dependent on Phase III trial results.

2020-01-15 · 0001193125-20-008059

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

The filing confirms the effectiveness of Menlo Therapeutics Inc.'s S-4 registration statement related to a merger with Foamix Pharmaceuticals Ltd. The merger involves exchanging Foamix ordinary shares for Menlo common stock, with exchange ratios contingent on the success of Menlo's Phase III clinical trials for serlopitant. The registration includes 120,609,872 shares of Menlo common stock, valued at $211.7 million, with a registration fee of $27,474.35. The transaction remains subject to clinical trial outcomes and regulatory approvals.

2020-01-07 · 9999999995-20-000023

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 425 and confirms the priced prospectus.

Exchange NASDAQ

VYNE Therapeutics Inc. (Foamix) is merging with Menlo Therapeutics Inc. under an agreement where Foamix shareholders will receive Menlo common stock and contingent stock rights (CSRs) dependent on the success of Menlo's Phase III trials for serlopitant. The merger's terms, including ownership percentages, hinge on the efficacy results of these trials, with potential adjustments to share allocations. The transaction requires shareholder approvals for both companies, with the merger expected to close before May 31, 2020.

2020-01-07 · 0001193125-20-003077

S-4/A amended

S-4/A

Pre-IPO filing captured from the SEC submission timeline.

Updates the prior EFFECT filing.

120,609,872 shares

Common Stock · Exchange Nasdaq Global Select Market · Ticker MNLO · Warrants to purchase Menlo common stock · Use of proceeds To facilitate the merger with Foamix Pharmaceuticals Ltd. · Flags foreign_private_issuer, warrants

The current S-4/A filing details the merger between Menlo Therapeutics Inc. and Foamix Pharmaceuticals Ltd., structured as a stock-for-stock transaction. The exchange ratio for Foamix shares depends on the success of Menlo's Phase III trials for serlopitant in treating prurigo nodularis (PN). If both trials succeed, Foamix shareholders receive 0.5924 Menlo shares (59% ownership). Partial or full trial failure adjusts the ratio to 1.2739 (76%) or 1.8006 (82%) respectively. The merger aims to create a combined dermatology-focused company with enhanced financials, contingent stock rights (CSRs), and a pro forma cash position of $169 million as of September 2019. The transaction is expected to close in March 2020, pending regulatory and shareholder approvals.

2020-01-06 · 0001193125-20-002234

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 424B4 in the pre-IPO sequence.

Menlo Therapeutics Inc. and Foamix Pharmaceuticals Ltd. are pursuing a strategic merger to create a combined dermatology-focused company. The transaction aims to enhance financial strength, expand pipeline opportunities, and leverage commercial infrastructure. Key milestones include Phase III trial results for serlopitant in Prurigo Nodularis (PN) and the launch of AMZEEQ and FMX103. The merger is subject to regulatory and shareholder approvals, with a projected close in March 2020.

2019-12-20 · 0001193125-19-319783

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows EFFECT in the pre-IPO sequence.

VYNE Therapeutics Inc. (Menlo Therapeutics) announced a special stockholder meeting scheduled for February 6, 2020, following the completion of a merger agreement with Foamix Pharmaceuticals Ltd. The filing references a pending merger, with details about shareholder voting and regulatory processes. The company emphasized the need for stockholders to review the joint proxy statement/prospectus for critical transaction details.

2019-12-16 · 0001193125-19-315290

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows S-1/A in the pre-IPO sequence.

The current 425 filing by Menlo Therapeutics Inc. provides details on severance benefits for employees in the event of a merger with Foamix Pharmaceuticals Ltd., including cash compensation, benefit continuation, and tax implications for stock options and RSUs. It references a pending merger and includes forward-looking statements about risks, while directing investors to the S-4 registration statement for additional information.

2019-12-09 · 0001193125-19-309348

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows CERT in the pre-IPO sequence.

Menlo Therapeutics Inc. amended its merger agreement with Foamix Pharmaceuticals Ltd. to adjust the voting requirements for issuing shares of Menlo common stock in connection with the merger. The amendment, effective December 4, 2019, modifies Section 4.4 of the Merger Agreement to clarify the vote needed for share issuance, ensuring alignment with regulatory and shareholder approval processes. The merger involves Giants Merger Subsidiary Ltd., a Menlo subsidiary, merging into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo.

2019-12-04 · 0001193125-19-306320

S-4 filed

S-4

Pre-IPO filing captured from the SEC submission timeline.

Follows 8-A12B in the pre-IPO sequence.

120,609,872 shares · Gross proceeds $211,666,776

Common Stock · Exchange Nasdaq Global Select Market · Ticker MNLO · Exchange ratio of 1.8006 shares of Menlo common stock per Foamix ordinary share · Use of proceeds To facilitate the merger with Foamix Pharmaceuticals Ltd.

Menlo Therapeutics Inc. is registering shares of its common stock for issuance to Foamix Pharmaceuticals Ltd. shareholders in connection with a proposed merger. The merger involves the exchange of Foamix ordinary shares for Menlo common stock, with the exchange ratio dependent on the results of Menlo's Phase III clinical trials for serlopitant. The registration includes shares issued upon completion of the merger, contingent stock rights (CSRs), and the potential for adjusted ownership percentages based on trial outcomes. Shareholder approvals are required for the merger under Israeli and U.S. law.

2019-12-04 · 0001193125-19-306313

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows S-1/A in the pre-IPO sequence.

The current filing by Menlo Therapeutics Inc. details the proposed merger with Foamix Pharmaceuticals Ltd., outlining terms, compensation, severance, and integration plans. The merger, structured as a stock swap, aims to create a combined dermatology company with a focus on product launches and clinical trial milestones. Key elements include severance protections for employees, equity vesting adjustments, and anticipated regulatory milestones for drugs like AMZEEQ and serlopitant. The filing also emphasizes transparency and transition planning ahead of the merger's expected closing in Q1-Q2 2020.

2019-11-21 · 0001193125-19-297587

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows S-1/A in the pre-IPO sequence.

The current filing announces a proposed merger between Menlo Therapeutics Inc. and Foamix Pharmaceuticals Ltd., aiming to create a stronger dermatology company. The merger combines Menlo's late-stage asset, serlopitant, with Foamix's approved product AMZEEQ and pipeline, enhancing operational efficiency, reducing financing needs, and enabling three product launches within two years. The transaction is structured as a stock-for-stock deal with contingent share adjustments based on Phase 3 trial outcomes for serlopitant.

2019-11-12 · 0001193125-19-289173

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows S-1 in the pre-IPO sequence.

VYNE Therapeutics Inc. (through its subsidiary Menlo Therapeutics) is merging with Foamix Pharmaceuticals Ltd. in a stock-for-stock transaction. The merger aims to create a stronger dermatology company by combining Foamix's topical minocycline products with Menlo's late-stage serlopitant program for prurigo nodularis (PN). The deal's exchange ratio depends on the outcome of Phase 3 trials for serlopitant, with potential revenue synergies and extended cash runway through 2021. The combined entity will be headquartered in the U.S., with Menlo as the surviving corporation.

2019-11-12 · 0001193125-19-289168

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows DRS/A in the pre-IPO sequence.

VYNE Therapeutics Inc. (Menlo Therapeutics) entered into a merger agreement with Foamix Pharmaceuticals Ltd., under which Foamix will merge into Menlo. The merger consideration includes Menlo common stock and contingent stock rights, with exchange ratios dependent on the efficacy of Phase III trials for prurigo nodularis. Governance changes include board composition, and the merger is subject to regulatory approvals and shareholder votes.

2019-11-12 · 0001193125-19-289144

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows DRS in the pre-IPO sequence.

VYNE Therapeutics Inc. (through its subsidiary Foamix Pharmaceuticals Ltd.) entered into a merger agreement with Menlo Therapeutics, Inc., resulting in a stock exchange and contingent stock rights based on Phase III trial outcomes. The merger terms include variable exchange ratios dependent on efficacy results, governance structure changes, and regulatory approvals.

2019-11-12 · 0001178913-19-002660

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

The Notice of Effectiveness indicates that Menlo Therapeutics Inc.'s S-3 registration statement became effective on February 12, 2019, allowing the company to offer securities. This follows an earlier 424B4 filing from January 2018 related to its initial public offering (IPO), which included details about the offering of 7,000,000 shares at $17.00 per share and underwriters like Jefferies, Piper Jaffray, and Guggenheim Securities.

2019-02-12 · 9999999995-19-000201

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $17.00 · 7,000,000 shares · Gross proceeds $110,670,000

Common · Exchange Nasdaq Global Select Market · Ticker MNLO · Over-allotment 1,050,000 · Underwriters Jefferies, Piper Jaffray, Guggenheim Securities

Menlo Therapeutics Inc. is conducting its initial public offering (IPO) to raise capital by selling 7,000,000 shares of common stock at $17.00 per share. The offering includes underwriters such as Jefferies, Piper Jaffray, and Guggenheim Securities, with an option for them to purchase additional shares. The company focuses on developing serlopitant for treating pruritus and refractory chronic cough, with Phase 3 trials planned for prurigo nodularis. The filing highlights the company's status as an emerging growth company and emphasizes risks related to clinical trials, regulatory approval, and reliance on a single product candidate.

2018-01-26 · 0001628280-18-000611

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

Menlo Therapeutics Inc. filed a Notice of Effectiveness for its S-1 registration statement, indicating the approval of its initial public offering (IPO). The company plans to offer 6.5 million shares of common stock at an expected price range of $16.00 to $17.00 per share. The offering includes an underwriter option to purchase an additional 975,000 shares. Proceeds will fund clinical trials, commercialization, and general operations. The company is an emerging growth company with reduced reporting requirements.

2018-01-24 · 9999999995-18-000207

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior 8-A12B filing.

Price $17.00 · Range $16.00 to $17.00 · 7,475,000 shares · Gross proceeds $127,075,000

Common Stock, $0.0001 par value per share · Exchange Nasdaq Global Select Market · Ticker MNLO · Over-allotment 975,000 · Use of proceeds working capital, clinical trials, and other general corporate purposes · Underwriters Jefferies, Piper Jaffray, Guggenheim Securities

VYNE Therapeutics Inc. is conducting an initial public offering (IPO) to raise capital by issuing 6.5 million shares of common stock at an expected price range of $16.00 to $17.00 per share. The company is developing serlopitant, a potential treatment for pruritus (itch) associated with dermatologic conditions and refractory chronic cough. Key clinical trials have shown positive results, with plans to advance to Phase 3 trials. The company is an 'emerging growth company' under the JOBS Act, which allows for reduced reporting requirements. The IPO is underwritten by Jefferies, Piper Jaffray, Guggenheim Securities, and JMP Securities.

2018-01-23 · 0001628280-18-000542

CERT inactive

CERT

Pre-IPO filing captured from the SEC submission timeline.

First tracked pre-IPO filing for this issuer.

The current filing is a CERT form for VYNE Therapeutics Inc., indicating a securities registration. The previous filing was an 8-A12B, which registered Common Stock on NASDAQ. The current filing's details are obscured in the provided text, suggesting a potential shift in registration type or scope.

2018-01-19 · 9999999997-18-000431

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

Follows S-1/A and registers the class of securities for exchange listing.

VYNE Therapeutics Inc. filed Form 8-A12B to register its common stock for listing on NASDAQ, incorporating by reference the capital stock description from its earlier S-1/A filing. The registration focuses on the company's late-stage biopharmaceutical pipeline, including serlopitant for pruritus and refractory chronic cough, with no explicit changes noted from the prior S-1/A filing.

2018-01-19 · 0001628280-18-000505

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Range $14.00 to $16.00 · 5,666,667 shares

Common Stock · Exchange Nasdaq Global Select Market · Ticker MNLO · Over-allotment 850,000 · Use of proceeds to fund operations and general corporate purposes · Underwriters Jefferies, Piper Jaffray, Guggenheim Securities

VYNE Therapeutics Inc. is conducting an initial public offering (IPO) of 5,666,667 shares of common stock, with an expected price range of $14.00 to $16.00 per share. The company is developing serlopitant, a selective NK1-R inhibitor, for treating pruritus associated with dermatologic conditions and refractory chronic cough. Phase 2 trial results showed statistically significant improvements in pruritus, with plans for Phase 3 trials in prurigo nodularis and ongoing trials for atopic dermatitis and psoriasis. The offering includes underwriter options for additional shares and mentions potential commercialization strategies.

2018-01-18 · 0001628280-18-000456

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Range $14.00 to $16.00 · 6,516,667 shares · Gross proceeds $104,266,672

Common Stock · Exchange Nasdaq Global Market · Ticker MNLO · Over-allotment 850,000 · Use of proceeds for working capital, clinical trials, and other general corporate purposes · Underwriters Jefferies, Piper Jaffray, Guggenheim Securities

VYNE Therapeutics Inc. (formerly Menlo Therapeutics) is a biopharmaceutical company focused on developing serlopitant for treating pruritus associated with dermatologic conditions and refractory chronic cough. The company is advancing Phase 2 trials for atopic dermatitis and psoriasis, and Phase 3 trials for prurigo nodularis. The IPO aims to raise capital to support clinical development, commercialization, and operational needs, with shares priced between $14.00 and $16.00 per share.

2018-01-12 · 0001628280-18-000299

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Gross proceeds $97,750,000

Common Stock, $0.0001 par value per share · Exchange Nasdaq Global Market · Ticker MNLO · Underwriters Jefferies, Piper Jaffray, Guggenheim Securities

VYNE Therapeutics Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise up to $97.75 million. The company focuses on developing serlopitant, a potential treatment for pruritus (itch) associated with dermatologic conditions like atopic dermatitis, psoriasis, and prurigo nodularis, as well as refractory chronic cough. Serlopitant, a neurokinin 1 receptor inhibitor, has shown promising results in Phase 2 trials, with plans for Phase 3 trials and potential regulatory submissions by 2020. The company is an emerging growth company and expects to list on the Nasdaq Global Market under the symbol 'MNLO.'

2017-12-28 · 0001628280-17-012730

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

VYNE Therapeutics Inc. (Menlo Therapeutics Inc.) is undergoing an initial public offering (IPO) to raise capital, with an anticipated offering price range of $X to $X per share. The company is developing serlopitant, a neurokinin 1 receptor inhibitor, for pruritus associated with dermatologic conditions and refractory chronic cough. The filing includes updated clinical trial data, underwriter details, and regulatory strategy for potential approvals in the U.S. and Europe.

2017-12-05 · 0001566044-17-000018

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

VYNE Therapeutics Inc. (referred to as Menlo Therapeutics Inc. in the filing) is conducting an initial public offering (IPO) to raise capital, with the registration statement submitted confidentially to the SEC. The company is a biopharmaceutical firm focused on developing serlopitant, a small molecule inhibitor of the neurokinin 1 receptor, for treating pruritus (itch) associated with dermatologic conditions and refractory chronic cough. The filing outlines plans for Phase 3 trials in prurigo nodularis, ongoing Phase 2 trials for atopic dermatitis and psoriasis, and potential regulatory approvals. The IPO includes underwriters Jefferies, Piper Jaffray, Guggenheim Securities, and JMP Securities. The company is classified as an emerging growth company, benefiting from reduced reporting requirements.

2017-10-30 · 0001566044-17-000010

VYNE Therapeutics Inc.

Filing Timeline

14 comparable deals

Recent News